SI-BONE INC (SIBN)
US8257041090 - Common Stock
Taking everything into account, SIBN scores 3 out of 10 in our fundamental rating. SIBN was compared to 192 industry peers in the Health Care Equipment & Supplies industry. While SIBN seems to be doing ok healthwise, there are quite some concerns on its profitability. SIBN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SIBN has reported negative net income.
SIBN had a negative operating cash flow in the past year.
SIBN had negative earnings in each of the past 5 years.
In the past 5 years SIBN always reported negative operating cash flow.
1.2 Ratios
SIBN has a Return On Assets (-19.27%) which is comparable to the rest of the industry.
SIBN has a Return On Equity of -26.05%. This is comparable to the rest of the industry: SIBN outperforms 58.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.27% | ||
| ROE | -26.05% | ||
| ROIC | N/A |
ROA(3y)-29.14%
ROA(5y)-27.96%
ROE(3y)-43.35%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 78.10%, SIBN belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
In the last couple of years the Gross Margin of SIBN has declined.
The Profit Margin and Operating Margin are not available for SIBN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.57%
GM growth 5Y-2.87%
2. Health
2.1 Basic Checks
SIBN does not have a ROIC to compare to the WACC, probably because it is not profitable.
SIBN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SIBN has more shares outstanding
SIBN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.07 indicates that SIBN is not in any danger for bankruptcy at the moment.
SIBN's Altman-Z score of 4.07 is fine compared to the rest of the industry. SIBN outperforms 71.35% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that SIBN is not too dependend on debt financing.
SIBN has a Debt to Equity ratio (0.22) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.07 |
ROIC/WACCN/A
WACC10.06%
2.3 Liquidity
SIBN has a Current Ratio of 9.76. This indicates that SIBN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 9.76, SIBN belongs to the best of the industry, outperforming 90.10% of the companies in the same industry.
SIBN has a Quick Ratio of 8.75. This indicates that SIBN is financially healthy and has no problem in meeting its short term obligations.
SIBN's Quick ratio of 8.75 is amongst the best of the industry. SIBN outperforms 90.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.76 | ||
| Quick Ratio | 8.75 |
3. Growth
3.1 Past
SIBN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.45%, which is quite impressive.
The Revenue has grown by 23.45% in the past year. This is a very strong growth!
The Revenue has been growing by 20.18% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)31.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.62%
Revenue 1Y (TTM)23.45%
Revenue growth 3Y23.69%
Revenue growth 5Y20.18%
Sales Q2Q%15.77%
3.2 Future
SIBN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.68% yearly.
The Revenue is expected to grow by 18.26% on average over the next years. This is quite good.
EPS Next Y14.76%
EPS Next 2Y13.9%
EPS Next 3Y15.68%
EPS Next 5YN/A
Revenue Next Year20.39%
Revenue Next 2Y18.23%
Revenue Next 3Y18.26%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SIBN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SIBN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SIBN's earnings are expected to grow with 15.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.9%
EPS Next 3Y15.68%
5. Dividend
5.1 Amount
SIBN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SI-BONE INC
NASDAQ:SIBN (5/31/2024, 7:05:48 PM)
After market: 14.05 0 (0%)14.05
+0.58 (+4.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap578.86M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.27% | ||
| ROE | -26.05% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 78.1% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.76 | ||
| Quick Ratio | 8.75 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)31.45%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y14.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)23.45%
Revenue growth 3Y23.69%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y